Atypical hemolytic uremic syndrome (aHUS) is a chronic, ultra-rare disease characterized by thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count and life-threatening damage to the kidney, brain, heart, and other vital organs. The signs and symptoms of aHUS result from the formation of tiny blood clots (microthrombi) in various small blood vessels of the body. These clots reduce or prevent proper blood flow to various organs of the body, especially the kidneys. Thus, aHUS is a complex disorder, and multiple factors, including certain genetic, environmental, and immunologic factors, all play a role in its development.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/atypical-hemolytic-uremic-syndrome-ahus-market
The Atypical Hemolytic Uremic Syndrome (aHUS) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Atypical Hemolytic Uremic Syndrome (aHUS) market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Atypical Hemolytic Uremic Syndrome (aHUS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Atypical Hemolytic Uremic Syndrome (aHUS) Market Key Facts
-
According to the National Organization for Rare Disorders (NORD), in childhood, aHUS affects males and females in equal numbers whereas, in adulthood, females are affected more often than males, most likely because pregnancy is a triggering event. Even though the exact overall incidence and prevalence is unknown, the incidence in the US is estimated to be 2 individuals per 1 million in the general population.
-
A study by Yoshida et al. (2017) titled, “Atypical hemolytic uremic syndrome”, estimated the annual incidence of aHUS to be two cases per million in the US, and the prevalence was reported to be 3.3 per million among patients below the age of 18. In France, an incidence of 0.23 cases per million was reported.
-
A study by Kato et al. (2016) titled, “Clinical guides for atypical hemolytic uremic syndrome in Japan” estimated that 2 per million adults and 3.3 per million children develop aHUS each year. Within the patient population considered for this study, approximately 40% of patients diagnosed with aHUS were under 18 years of age.
-
As per the NORD, in childhood, aHUS affects males and females in equal numbers whereas, in adulthood, females are affected more often than males by aHUS.
Key Benefits of Atypical Hemolytic Uremic Syndrome (aHUS) Market Report
-
The market report provides an in-depth analysis of Atypical Hemolytic Uremic Syndrome (aHUS) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Atypical Hemolytic Uremic Syndrome (aHUS) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Atypical Hemolytic Uremic Syndrome (aHUS) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Atypical Hemolytic Uremic Syndrome (aHUS) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Atypical Hemolytic Uremic Syndrome (aHUS) Market
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Atypical Hemolytic Uremic Syndrome (aHUS) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Atypical Hemolytic Uremic Syndrome (aHUS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics Market Assessment
Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology
The epidemiology section covers insights about the historical and current Atypical Hemolytic Uremic Syndrome (aHUS) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Atypical Hemolytic Uremic Syndrome (aHUS) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atypical Hemolytic Uremic Syndrome (aHUS) market or expected to get launched in the market during the study period. The analysis covers Atypical Hemolytic Uremic Syndrome (aHUS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Atypical Hemolytic Uremic Syndrome (aHUS) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
aHUS has a dry pipeline with few emerging therapies in the late phase of clinical development. The therapies are expected to launch during the forecast period.
Some of the key companies in the Atypical Hemolytic Uremic Syndrome (aHUS) Market include:
-
Akari Therapeutics
-
Alexion Pharmaceuticals
-
Omeros Corporation
And many others.
Atypical Hemolytic Uremic Syndrome (aHUS) Therapies covered in the report include:
-
Narsoplimab
-
Nomacopan
And Others.
Due to such skim pipeline activity, the aHUS is facing a serious unmet need which suggests that there is a high need for the development of novel therapies for the treatment of patients suffering from aHUS.
Table of Content
1. Key Insights
2. Executive Summary
3. Atypical Hemolytic Uremic Syndrome (aHUS) Competitive Intelligence Analysis
4. Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance
5. Atypical Hemolytic Uremic Syndrome (aHUS) Disease Background and Overview
6. Atypical Hemolytic Uremic Syndrome (aHUS) Patient Journey
7. Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology and Patient Population
8. Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Algorithm, Current Treatment, and Medical Practices
9. Atypical Hemolytic Uremic Syndrome (aHUS) Unmet Needs
10. Key Endpoints of Atypical Hemolytic Uremic Syndrome (aHUS) Treatment
11. Atypical Hemolytic Uremic Syndrome (aHUS) Marketed Products
12. Atypical Hemolytic Uremic Syndrome (aHUS) Emerging Therapies
13. Atypical Hemolytic Uremic Syndrome (aHUS) Seven Major Market Analysis
14. Attribute Analysis
15. Atypical Hemolytic Uremic Syndrome (aHUS) Market Outlook (7 major markets)
16. Atypical Hemolytic Uremic Syndrome (aHUS) Access and Reimbursement Overview
17. KOL Views on the Atypical Hemolytic Uremic Syndrome (aHUS) Market.
18. Atypical Hemolytic Uremic Syndrome (aHUS) Market Drivers
19. Atypical Hemolytic Uremic Syndrome (aHUS) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/atypical-hemolytic-uremic-syndrome-ahus-market
Latest Reports By DelveInsight
Atypical Hemolytic Uremic Syndrome Pipeline Insights
Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Atypical Hemolytic Uremic Syndrome (aHUS) Market.
Lymphatic Malformations Market
DelveInsight’s “Lymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lymphatic Malformations market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/